tdf

In this episode, Paul E. Sax, MD, discusses emerging drug therapies and treatment options for patients with HIV, including rapid initiation of ART, long-acting ART, and 2-drug ART regimens. The overview will include analyses from:

• The RAPID ART program in San Francisco, where same-day initiation of ART led to faster HIV-1 RNA suppression that was maintained at greater than 92% during a 3-year period
• The DIAMOND study analyzing virologic efficacy and safety at 48 weeks after initiating DRV/COBI/FTC/TAF within 24 hours of HIV infection diagnosis
• A rapid ART start program in young PWH in New Orleans that demonstrated achievement of viral suppression in fewer than 30 days and no discontinuations due to adverse events
• The ATLAS (including ATLAS-2M) and FLAIR studies that demonstrated efficacy and safety of long-acting injectable CAB plus RPV
• SWORD-1 and SWORD-2 that demonstrated switching to a 2-drug regimen of DTG plus RPV in virologically suppressed adults was safe and effective
• GEMINI-1 and GEMINI-2 that demonstrated noninferiority of DTG plus 3TC compared with DTG plus FTC/TDF
• TANGO that demonstrated safety and efficacy of switching to DTG/3TC in virologically suppressed adults receiving a TAF-based regimen

In addition, Dr. Sax reviews current recommendations by the DHHS, WHO, and IAS-USA regarding these emerging therapies and treatment paradigms.  

Presenter:

Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Follow along with the slides at:
https://bit.ly/3zdPwm2 

Content based on an online CME program supported by an educational grant from ViiV Healthcare.

Link to full program:
https://bit.ly/3ux6FF8

In this episode, David A. Wohl, MD, discusses current guidelines and clinical trial data informing optimal selection of first-line antiretroviral therapy for HIV.

David A. Wohl, MD    
Professor of Medicine
School of Medicine
Site Leader, AIDS Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Director, North Carolina AIDS Training and Education Center
Chapel Hill, North Carolina
Co-Director, HIV Services
North Carolina Department of Correction
Raleigh, North Carolina

Link to full program:
https://bit.ly/3ux6FF8

In this episode, William R. Short, MD, MPH, AAHIVS, discusses current guidelines and clinical trial data informing optimal selection of first-line antiretroviral therapy for HIV.

William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine  
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Content based on a CME program supported by an independent educational grant from ViiV Healthcare.

Link to full program:
https://bit.ly/3ux6FF8

In this episode, Drs José R. Arribas, Andrew Carr, and Lynora Saxinger discuss simplification strategies for a virologically suppressed patient with HIV and a complex ART treatment history.

Presenters:

José R. Arribas, MD
Research Director, HIV and Infectious Diseases
Hospital La Paz IdiPAZ
Madrid, Spain

Andrew Carr, MBBS, MD, FRACP, FRCPA
Professor of Medicine
University of New South Wales
Director, HIV and Immunology Unit
St Vincent’s Hospital
Sydney, Australia

Lynora Saxinger, MD, FRCPC, CTropMed
Cochair, Scientific Advisory Group
Alberta COVID-19 Emergency
Coordination Centre
Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Alberta
Edmonton, Alberta
Canada

Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.

Link to full program:
https://bit.ly/3xdgcTk

In this episode, Drs José R. Arribas, Andrew Carr, and Lynora Saxinger discuss ART safety and management in a woman who wishes to conceive.

Presenters:

José R. Arribas, MD
Research Director, HIV and Infectious Diseases
Hospital La Paz IdiPAZ
Madrid, Spain

Andrew Carr, MBBS, MD, FRACP, FRCPA
Professor of Medicine
University of New South Wales
Director, HIV and Immunology Unit
St Vincent’s Hospital
Sydney, Australia

Lynora Saxinger, MD, FRCPC, CTropMed
Cochair, Scientific Advisory Group
Alberta COVID-19 Emergency
Coordination Centre
Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Alberta
Edmonton, Alberta
Canada

Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.

Link to full program:
https://bit.ly/3xdgcTk

In this episode, Drs José R. Arribas, Andrew Carr, and Lynora Saxinger discuss weight gain concerns for a patient with initiating ART.

Presenters:

José R. Arribas, MD
Research Director, HIV and Infectious Diseases
Hospital La Paz IdiPAZ
Madrid, Spain

Andrew Carr, MBBS, MD, FRACP, FRCPA
Professor of Medicine
University of New South Wales
Director, HIV and Immunology Unit
St Vincent’s Hospital
Sydney, Australia

Lynora Saxinger, MD, FRCPC, CTropMed
Cochair, Scientific Advisory Group
Alberta COVID-19 Emergency
Coordination Centre
Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Alberta
Edmonton, Alberta
Canada

Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.

Link to full program:
https://bit.ly/3xdgcTk

In this episode, Brian Wood, MD, discusses HIV treatment safety and tolerability data from 2020 conferences and addresses how he manages ARV-associated weight gain his patients and how the latest data on ART safety during conception and pregnancy impact his treatment recommendations.

Presenters:

Brian Wood, MD
Associate Professor of Medicine
Division of Allergy and Infectious Diseases
University of Washington
Seattle, Washington

Content based on an online CME/CE/CPE-certified program supported by educational grants from Janssen Therapeutics, Division of Janssen Products, LP.

Link to full program:
https://bit.ly/38YZVrz

In this episode, Dr. Joseph Eron and Dr. Jason Halperin discuss caring for complex HIV cases, including patients with underlying resistance or comorbidities.

Presenters:

Joseph J. Eron, Jr., MD
Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Jason Halperin, MD, MPH
Assistant Professor of Medicine
Department of Infectious Diseases
Tulane University
Infectious Disease Physician
CrescentCare
New Orleans, Louisiana

Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.

Link to full program:
https://bit.ly/34fVILZ

In this episode, W. David Hardy, MD, discusses current guidelines and clinical trial data informing optimal selection of first-line antiretroviral therapy for HIV.

Presenter:

W. David Hardy, MD
Scientific and Medical Consultant
Adjunct Professor of Medicine
Division of Infectious Diseases 
Johns Hopkins University School of Medicine
Baltimore, Maryland

Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.

Link to full program:
https://bit.ly/34fVILZ

Tom got into engineering to gain further understanding in the world around him.  And he realised there was so much still unknown, especially in the area of safety engineering.  He has realised the key is to keep innovating... “keep anticipating where things might go wrong”. And that even when it seems difficult or too much of a challenge, to not shy away. 

This is a podcast about the engineering challenges that are facing today’s society.
These are our Engineering Heroes. A podcast from Engineers Australia.

Your hosts are Melanie and Dominic De Gioia

See omnystudio.com/listener for privacy information.

Geoff, Josh and Gerry review the first 3 stages of the 2020 Tour de France. Rain, crashes, Jumbo Visma leading the way, Julian Alaphilippe, another excellent 22 year old talent and an impressive sprint by Caleb Ewan!

What will the next 5 days bring us, who are the riders that will perform as expected and do the guys predict any surprises?

It is without a doubt a different TdF and Geoff, Josh and Gerry talk about covid and if the organization is using this year to test out certain concepts that they might have wanted, but never dared. "never change a successful formula".

Enjoy the listen and don't forget to stay healthy, safe and happy!

Geoff & Gerry preview the 2020 Tour de France together with our special guest and friend of the show Josh Wagner.

The show actually starts with Geoff asking Gerry to talk about his cycling background. Gerry goes into details how he started with cycling and makes a number of references to the Tour de France and riding in France.

Geoff, Josh and Gerry share their opinions on general classification, who has the strongest team, what will the different stages bring us, will there be a surprise....or two... and finally they make their predictions.

Hope you enjoy the show and look forward to the start of the Tour the France as much as we do.

Tour de France talk starts at minute 17:00

https://www.letour.fr/en/

In today’s podcast, Geoff and Gerry speak with Daniel Larson.

Daniel works as an assistant professor at the University of Oklahoma, Department of Health and Exercise Science. His primary field of expertise is Economic theory in sport; finance and policy for international professional sports; management of national governing bodies (like USAC); participant sport-event management; public finance for sports/exercise interventions; and sport coaching/instruction.

In addition to his work for the University of Oklahoma, Daniel has a wealth of experience as an elite cyclist both on the track and on the road, sports director for the Jittery Joe’s U23 team, Director of Athletics VMG Racing, Head Cycling Coach University of Florida, and event organizer/promotor.

You might recall one of our previous podcast with Rebeca Larson!  Quoting Daniel in this interview: “it's interesting because we ride together, and we work together, and we're in the same department”. If you haven’t listened to Rebeca’s podcast yet, we highly recommend you do! https://podcasts.apple.com/us/podcast/the-n-1-cycling-podcast-by-lowlands-cycling/id1507687751?i=1000484284558

Daniel starts the podcast with how he got started with cycling at the age of 14 and his under graduate and graduate studies, all in the field of business and exercise & sport science.

We talk about Daniels time as a sport director and he shares the good the bad and the ugly looking back at his different tenures in this role.

During a very interesting segment of this podcast we talk about the “12k dreamers”. Young professional cyclist that are paid a $1,000 per month and dream about a contract with a bigger team. Daniel talks about his research in this area and the data he gathered which paint a striking picture. We talk about romanticizing the life of a professional cyclist and the ambition to stay professional. At what cost? Daniel states that normally you can identify how much talent someone has within no more than 2 years of working with young cyclists. An highly talented cyclist usually moves through the ranks showing his/her capabilities and talent and wont deviate much getting older. Cycling talent is comprised of the right DNA and genes. “they're fortunate to have they're gifted this physical gift or genetic gift and they're able to capitalize on it”.

Daniel wrote a book about the economics of professional cycling (the only book to date!) with colleague from Belgium (Kortrijk). We discuss differences between Europe and the US in regards to nurturing talent and the path to becoming a professional cyclist.

With the Tour de France starting in a couple of weeks, we asked Daniels view on teams like Jumbo-Visma and Ineos who will bring multiple potential TdF winners and what this does to the team dynamic from a Director and a Domestique point of view. Based on research, Daniel is able to break it down to facts explaining what will happen to teams in this position.

There are many more topics we discuss related to team and athlete agent economics.

This is an 80 minutes fully loaded podcast with a ton of value in the field of cycling and sports management. Enjoy!!

Episode Ten of the Endurance Sports Running podcast with Anthony Clark @fragilerunner and Stephen Cook @rustytrowel. For episode Ten we had the pleasure of speaking with Peter Thompson, in a part two of his interview where we talk about Running The Tour

Follow Maurten on Instagram & Twitter

The Podcast and show is now available to follow on Spotify and subscribe on iTunes / Apple Podcasts.  Please show your support by giving us a Rate & Review.

HOW TO CONTACT THE ENDURANCE FUELLED PODCAST:
GROUP: https://www.facebook.com/groups/endurancefuelled
STRAVA: https://www.strava.com/clubs/endurance-fuelled
URL: http://ef-podcast.com/
RSS: https://feeds.buzzsprout.com/239636.rss